Lastest from Businesswire
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten publ
Interactive Brokers Launches Access to Korean Equities, Breaking New Ground for Global Investors
GREENWICH, Conn.--(BUSINESS WIRE)-- #IBKR--Interactive Brokers (Nasdaq: IBKR) today announced the launch of access to equities listed on the Korea Exchange (KRX),

